So in severe vWF deficiency, factor VIII gets broken down faster and can become deficient, too.

在vWF缺乏严重时，因子VIII会更快被分解，继而也出现缺乏。

Desmopressin stimulates vWF release from endothelial cells, which promotes the stabilization of the residual factor VIII.

去氨加压素刺激血管性血友病因子vWF从内皮细胞释放，这能增强剩余因子VIII的稳定性。

For hemophilia A, desmopressin, also called DDAVP (1-deamino-8-D-arginine vasopressin) is helpful for patients with mild, quantitative factor VIII deficiency.

对于血友病A，去氨加压素（DDAVP）有助于治疗轻症因子VIII数量缺乏。

The factor V degradation product also binds to this complex and further enhances its ability to cleave more active factor V and active factor VIII.

V因子的分解产物也结合到复合物上，进一步增强了裂解更多活跃的V因子和VIII因子的能力。

This increases circulating factor V and factor VIII levels, and " tips the scale" toward coagulation, putting them at increased risk for thrombosis, or developing blood clots.

这使得血液循环中V因子和VIII因子数量增多，更容易发生凝血，导致血栓形成的风险增加。

By far the most common of these are deficiencies of factor VIII which gives rise to factor VIIIa and is stabilized by another factor called von Willebrand factor.

目前为止，大多数的血友病通常是因子VIII缺乏症；因子VIII能转变为因子VIIIa，并被血管性血友病因子（vWF）固定。